GlobeStar Therapeutics Co. (OTCMKTS:GSTC) Sees Significant Decrease in Short Interest

GlobeStar Therapeutics Co. (OTCMKTS:GSTC) saw a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 3,200 shares, a decrease of 91.0% from the January 31st total of 35,600 shares. Based on an average daily volume of 10,934,400 shares, the short-interest ratio is currently 0.0 days.

GlobeStar Therapeutics Trading Up 50.0 %

GlobeStar Therapeutics stock traded up $0.00 during trading hours on Friday, hitting $0.00. The company had a trading volume of 24,644 shares, compared to its average volume of 4,093,095. GlobeStar Therapeutics has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.

GlobeStar Therapeutics Company Profile

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc and changed its name to GlobeStar Therapeutics Corporation in July 2021.